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Abstract
Introduction
Screening for chromosome abnormalities prenatally is a 
complex topic and should be employed as an essential 
component of comprehensive obstetrical care. Various 
screening options are available to screen for the most 
common fetal aneuploidies, namely Trisomy 21 (Down 
syndrome), Trisomy 18, and Trisomy 13. Each screening 
tool has advantages and disadvantages, and informed 
decision making between patient and provider is 
essential for selection of which screen suits each patient, 
if any.
The traditional methods of screening will be compared to 
NIPS including gestational age at which these screens 
may be performed, sensitivity and specificity for Trisomy 
13, 18, and 21, and for which populations these screens 
are most appropriate.
Research Question
Literature Review
Applicability to Clinical 
Practice
Acknowledgements 
Discussion: Should cfDNA 
replace traditional methods?
According to a survey published by the Journal of Maternal-
Fetal and Neonatal Medicine in September of 2016, 
obstetric care providers identified NIPS as clinically superior 
to other screening tools (Brewer, Demers, & Musci, 2016). 
The survey stated that 81.5% of respondents believed that 
NIPS is a superior test in screening for aneuploidy 
regardless of maternal age. The survey also stated that most 
respondents would like ACOG to formally recommend this 
screening tool to all pregnant women, regardless of age.
In 2011, advances in research in medical genetics 
led to the advent of prenatal cell-free DNA (cfDNA) 
or also known simply as non-invasive prenatal 
screening or testing (NIPS). This screen consists of 
analyzation of placental DNA circulating in 
maternal blood. NIPS has had a major impact on 
prenatal screening for aneuploidy. Mixed opinions 
and data exist as to whom this test is most 
appropriate for.  The sensitivity and specificity of this 
screen in detecting common fetal aneuploidies has 
been well documented as superior to other screens 
in high-risk populations, but less so in low- risk 
obstetric populations. This paper will compare and 
contrast NIPS to more traditional screening methods 
such as first trimester maternal serum biochemical 
assay of human chorionic gonadotropin (hCG) and 
pregnancy associated plasma protein A (PAPP-A), 
and second trimester markers which include hCG, 
unconjugated estriol, inhibin A, and maternal serum 
alpha-fetoprotein.
Why should prenatal screening be offered? What are the 
current options for screening for fetal aneuploidy? Should 
NIPS replace standard screening for aneuploidy?  
.
Why should prenatal screening be offered?
It is been well documented that the risk of carrying a fetus 
affected by any chromosome abnormality increases with 
maternal age.
The research as stated in this review is highly applicable to 
clinical practice due to the fact that offering prenatal screening 
for aneuploidy to all women is an important part of providing 
comprehensive obstetric care.  Physician Assistants in both the 
primary care setting and women’s health setting may be 
providing obstetric care to patients, and knowledge of not only 
the existence of chromosome alterations but how to screen for 
them is of upmost importance in providing quality care. ACOG 
recommends offering screening to every pregnant patient. 
Knowledge of the benefits, limitations, and drawbacks of each 
screening test is an integral part of appropriate genetic 
counseling. 
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Statement of the Problem
With an increase in the amount of options for screening 
for fetal aneuploidy, awareness and understanding of the 
disadvantages and advantages of each screening tool is 
necessary in providing comprehensive obstetric care. 
Patients must first be counseled on the existence and 
possibility of fetal chromosome abnormalities; and 
informed decision making between patient and provider 
should ensue regarding which, if any, screening tool best 
suits the patient. 
References
•American College of Obstetrics and Gynecologists Committee on 
Genetics, Society for Maternal-Fetal Medicine. (2015). Committee 
Opinion Number 640: Cell-free DNA Screening for Fetal Aneuploidy. 
Obstetrics & Gynecology, 125(6), 1544-1547. 
doi:10.1097/01.AOG.0000466370.86393.d2
•American College of Obstetrics and Gynecologists, Society for Maternal-
Fetal Medicine. (2016). Practice Bulletin Number 163: Screening for Fetal 
Aneuploidy. Obstetrics and Gynecology, 127(5), 979-981. 
doi:10.1097/AOG.0000000000001439 [doi]
•Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., 
Das, A. F., . . . Sehnert, A. J. (2014). DNA sequencing versus standard 
prenatal aneuploidy screening. New England Journal of Medicine, 370(9), 
799-808. Doi:10.1056/NEJMoa1311037  
•Brewer, J., Demers, L., & Musci, T. (2016). Survey of US obstetrician 
opinions regarding NIPT use in general practice: Implementation and 
barriers. The Journal of Maternal-Fetal & Neonatal Medicine : The Official 
Journal of the European Association of Perinatal Medicine, the Federation 
of Asia and Oceania Perinatal Societies, the International Society of 
Perinatal Obstetricians, , 1-4. doi:10.1080/14767058.2016.1225035 [doi]
•Gregg, A. R., Skotko, B. G., Benkendorf, J. L., Monaghan, K. G., Bajaj, 
K., Best, R. G., . . . Watson, M. S. (2016). Noninvasive prenatal screening 
for fetal aneuploidy, 2016 update: a position statement of the American 
College of Medical Genetics and Genomics. Genetics in Medicine,18(10), 
1056-1065. doi:10.1038/gim.2016.97
What are the current options for screening for 
aneuploidy?
• First trimester screening: Maternal serum hCG and 
PAPP-A  + nuchal translucency ultrasound at 11 to 
14 weeks
• Second trimester screening:  Quad screen analyzes 
four biochemical markers which include hCG
levels, alpha-fetoprotein, unconjugated estriol, and 
dimeric inhibin A. 
• Integrated/Sequential screening: First trimester 
nuchal translucency study with ultrasound, hCG
and PAPP-A levels, as well as a second trimester 
quad screen
• NIPT/cfDNA: Analyzation of placental DNA 
circulating in maternal blood
Advantages of NIPS:
• High detection rates for the most common 
aneuploidies
• Can be performed any time after 10 weeks 
gestation
• Only one blood draw needed
Disadvantages of NIPS
• Only detects Trisomy 21, 18, and 13
• Mixed data on PPV in non high-risk populations
• Unreliable with multiples
(ACOG, 2016)
(ACOG, 2016)
